- Home
- DOV vs BIIB Comparison
DOV vs BIIB Comparison
Compare DOV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOV
- BIIB
- Stock Information
- Founded
- DOV 1947
- BIIB 1978
- Country
- DOV United States
- BIIB United States
- Employees
- DOV N/A
- BIIB N/A
- Industry
- DOV Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DOV Industrials
- BIIB Health Care
- Exchange
- DOV Nasdaq
- BIIB Nasdaq
- Market Cap
- DOV 25.8B
- BIIB 18.8B
- IPO Year
- DOV N/A
- BIIB 1991
- Fundamental
- Price
- DOV $188.89
- BIIB $133.99
- Analyst Decision
- DOV Buy
- BIIB Buy
- Analyst Count
- DOV 12
- BIIB 27
- Target Price
- DOV $206.50
- BIIB $188.17
- AVG Volume (30 Days)
- DOV 918.0K
- BIIB 1.3M
- Earning Date
- DOV 07-24-2025
- BIIB 07-31-2025
- Dividend Yield
- DOV 1.08%
- BIIB N/A
- EPS Growth
- DOV 59.80
- BIIB 26.39
- EPS
- DOV 16.60
- BIIB 10.12
- Revenue
- DOV $7,728,249,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- DOV $4.05
- BIIB N/A
- Revenue Next Year
- DOV $4.58
- BIIB N/A
- P/E Ratio
- DOV $25.19
- BIIB $13.27
- Revenue Growth
- DOV 3.19
- BIIB 1.59
- 52 Week Low
- DOV $143.04
- BIIB $110.04
- 52 Week High
- DOV $222.31
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- DOV 64.02
- BIIB 56.84
- Support Level
- DOV $186.86
- BIIB $129.08
- Resistance Level
- DOV $192.41
- BIIB $137.84
- Average True Range (ATR)
- DOV 2.91
- BIIB 4.01
- MACD
- DOV 0.68
- BIIB 0.57
- Stochastic Oscillator
- DOV 81.82
- BIIB 70.81
About DOV Dover Corporation
Founded in 1955 by George Ohrstrom, Dover has become an industrial behemoth through the acquisition of dozens of esteemed brands. The company is organized into five segments through which it designs and manufactures highly engineered components, such as vehicle repair, factory automation, welding, aerospace, fuel dispensing, printing, liquid handling, refrigeration, and can-making equipment. It has operations around the globe but generates over half of its revenue in the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.